Total Payments
$90,618
2024 Payments
$1,854
Companies
37
Transactions
702
Medicare Patients
40,649
Medicare Billing
$6.6M
Payment Breakdown by Category
Other$67,382 (74.4%)
Food & Beverage$19,019 (21.0%)
Travel$4,163 (4.6%)
Education$53.59 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $67,382 | 28 | 74.4% |
| Food and Beverage | $19,019 | 653 | 21.0% |
| Travel and Lodging | $4,163 | 12 | 4.6% |
| Education | $53.59 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $28,782 | 33 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $16,375 | 36 | $0 (2021) |
| Gilead Sciences, Inc. | $16,245 | 38 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $14,052 | 18 | $0 (2019) |
| Abbott Laboratories | $1,939 | 33 | $0 (2024) |
| Amgen Inc. | $1,920 | 64 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,670 | 60 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,283 | 58 | $0 (2024) |
| PFIZER INC. | $1,146 | 51 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,072 | 55 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,854 | 80 | Esperion Therapeutics, Inc. ($240.34) |
| 2023 | $1,911 | 66 | E.R. Squibb & Sons, L.L.C. ($413.12) |
| 2022 | $1,816 | 80 | PFIZER INC. ($284.27) |
| 2021 | $2,062 | 70 | Janssen Pharmaceuticals, Inc ($413.60) |
| 2020 | $1,630 | 70 | Janssen Pharmaceuticals, Inc ($268.72) |
| 2019 | $17,302 | 98 | SANOFI-AVENTIS U.S. LLC ($10,318) |
| 2018 | $26,886 | 101 | SANOFI-AVENTIS U.S. LLC ($13,205) |
| 2017 | $37,158 | 137 | Kowa Pharmaceuticals America, Inc. ($13,279) |
All Payment Transactions
702 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Cardiology | ||||||
| 12/12/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $23.85 | General |
| Category: NEUROLOGY | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.55 | General |
| Category: Cardiovascular | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $2.26 | General |
| Category: Cardiovascular | ||||||
| 12/05/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/05/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $23.29 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.25 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/14/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: Diabetes | ||||||
| 11/13/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $5.72 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/04/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.29 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/07/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $32.18 | General |
| Category: Cardiology | ||||||
| 09/30/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/19/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/10/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: Not Applicable | ||||||
| 09/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.27 | General |
| Category: Cardiovascular | ||||||
| 09/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 34 | 11,282 | 15,723 | $5.4M | $1.7M |
| 2022 | 41 | 9,810 | 15,099 | $4.9M | $1.6M |
| 2021 | 48 | 9,921 | 17,030 | $5.2M | $1.8M |
| 2020 | 45 | 9,636 | 14,021 | $4.5M | $1.5M |
Total Patients
40,649
Total Services
61,873
Medicare Billing
$6.6M
Procedure Codes
175
All Medicare Procedures & Services
175 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 1,399 | 1,475 | $958,750 | $250,465 | 26.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 959 | 975 | $580,300 | $178,594 | 30.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,079 | 1,513 | $340,300 | $173,478 | 51.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,221 | 1,983 | $303,125 | $161,492 | 53.3% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 730 | 740 | $518,000 | $160,421 | 31.0% |
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 191 | 197 | $364,450 | $159,521 | 43.8% |
| 93978 | Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | Office | 2023 | 540 | 545 | $239,825 | $85,834 | 35.8% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 265 | 268 | $134,000 | $61,870 | 46.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 119 | 374 | $65,450 | $40,628 | 62.1% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 727 | 736 | $220,800 | $35,056 | 15.9% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 117 | 125 | $112,500 | $30,180 | 26.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 150 | 186 | $74,400 | $29,429 | 39.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 193 | 193 | $53,075 | $29,162 | 54.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 79 | 641 | $128,200 | $28,530 | 22.3% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 45 | 140 | $49,000 | $27,545 | 56.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,442 | 2,076 | $156,425 | $26,049 | 16.7% |
| 92928 | Insertion of stents with balloon dilation of coronary artery or branch, single artery or branch | Facility | 2023 | 40 | 44 | $83,600 | $25,436 | 30.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 65 | 664 | $199,200 | $24,031 | 12.1% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 74 | 402 | $54,650 | $23,051 | 42.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 53 | 392 | $78,400 | $18,701 | 23.9% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 726 | 735 | $220,500 | $16,354 | 7.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 105 | 192 | $28,800 | $13,872 | 48.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 151 | 184 | $38,640 | $13,605 | 35.2% |
| 92920 | Balloon dilation of single coronary artery or branch | Facility | 2023 | 38 | 42 | $84,000 | $11,904 | 14.2% |
| 93460 | Insertion of tube in right and left heart chambers and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 28 | 28 | $69,000 | $9,855 | 14.3% |
About Dr. Meyer Abittan, M.D
Dr. Meyer Abittan, M.D is a Specialist healthcare provider based in Roslyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548248339.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Meyer Abittan, M.D has received a total of $90,618 in payments from pharmaceutical and medical device companies, with $1,854 received in 2024. These payments were reported across 702 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($67,382).
As a Medicare-enrolled provider, Abittan has provided services to 40,649 Medicare beneficiaries, totaling 61,873 services with total Medicare billing of $6.6M. Data is available for 4 years (2020–2023), covering 175 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Roslyn, NY
- Active Since 01/03/2006
- Last Updated 03/30/2011
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1548248339
Products in Payments
- PRALUENT (Drug) $28,695
- Livalo (Drug) $16,375
- Ranexa (Drug) $15,921
- PRALUENT ALIROCUMAB INJECTION (Biological) $9,012
- PRALUENT (Biological) $5,040
- ELIQUIS (Drug) $1,688
- XARELTO (Drug) $1,670
- Repatha (Biological) $1,341
- Asahi Fielder coronary guide wire (Device) $1,028
- ENTRESTO (Drug) $782.95
- VERQUVO (Drug) $595.17
- Corlanor (Drug) $574.89
- KENGREAL (Drug) $565.56
- FARXIGA (Drug) $478.45
- PRADAXA (Drug) $463.42
- BRILINTA (Drug) $401.71
- CAMZYOS (Drug) $328.71
- JARDIANCE (Drug) $319.36
- MitraClip System (Device) $269.19
- LEQVIO (Drug) $261.81
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Roslyn
Dr. George Petrossian, M.d, M.D
Specialist — Payments: $28,992
Specialist $28,992
Dr. Ari Ezratty
Specialist — Payments: $21,900
Specialist $21,900
Dr. Andrew Lituchy, Md, MD
Specialist — Payments: $21,448
Specialist $21,448
Dr. Edward Oruci, M.d, M.D
Specialist — Payments: $16,646
Specialist $16,646
Dr. Kaupin Brahmbhatt, M.d, M.D
Specialist — Payments: $12,793
Specialist $12,793
Lisa Phillips, M.d, M.D
Specialist — Payments: $1,297
Specialist $1,297